Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with prostate-specific antigen in prostatic carcinoma.

I Romics1, D Bach

  • 1Department of Urology, St. Agnes Hospital, Bocholt, FRG.

International Urology and Nephrology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors during pregnancy and birth-related complications in HIV-positive versus HIV-negative women in Denmark, 2002-2014.

HIV medicine·2019
Same author

[Scientific activity of the University Urological Department in Budapest after WWII (1946-1956)].

Der Urologe. Ausg. A·2016
Same author

Mimicking biophysical stimuli within bone tumor microenvironment.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2016
Same author

A review of selected pumping systems in nature and engineering--potential biomimetic concepts for improving displacement pumps and pulsation damping.

Bioinspiration & biomimetics·2015
Same author

WITHDRAWN: Modulation of the kinetics of 3β-hydroxy-5-oxo-5,6-secocholestan-6-al/phosphatidylethanolamine Schiff base formation by cholesterol and cholesterol crystallization.

Chemistry and physics of lipids·2015
Same author

Modulation of the kinetics of 3β-hydroxy-5-oxo-5,6-secocholestan-6-al/phosphatidylethanolamine Schiff base formation by cholesterol and cholesterol crystallization.

Chemistry and physics of lipids·2015

Prostate-specific antigen (PSA) is the most effective biomarker for detecting prostate cancer and monitoring treatment response in patients with prostate tumors and adenoma. PSA levels accurately reflect disease progression over time.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Prostate cancer and benign prostatic hyperplasia are common conditions in aging men.
  • Accurate diagnostic markers are crucial for differentiating between prostate tumors and adenoma.
  • Biochemical markers play a vital role in prostate cancer diagnosis and management.

Purpose of the Study:

  • To evaluate the diagnostic and prognostic utility of prostate-specific antigen (PSA) and other prostatic enzymes.
  • To compare the effectiveness of PSA, prostatic acid phosphatase (PAP), serum prostatic phosphatase (SPP), and enzymic serum phosphatase in prostate disease.
  • To assess the role of PSA in monitoring therapeutic response and disease course.

Main Methods:

  • Serum levels of PSA, PAP, SPP, and enzymic serum phosphatase were measured.

Related Experiment Videos

  • Patients included 71 with prostatic tumors and 45 with prostatic adenoma.
  • Clearance tests and follow-up assessments were conducted during and after therapy.

    • Main Results:

    • Prostate-specific antigen (PSA) demonstrated the highest percentage of pathological affection across all stages in untreated patients.
    • PSA levels showed a strong correlation with the disease course, as indicated by clearance tests and long-term follow-up.
    • PSA proved to be a more sensitive marker compared to PAP, SPP, and enzymic serum phosphatase.

    Conclusions:

    • Prostate-specific antigen (PSA) is a highly effective biomarker for diagnosing prostate cancer and adenoma.
    • PSA is superior to other tested markers in identifying pathological conditions of the prostate.
    • PSA monitoring is valuable for assessing treatment efficacy and predicting disease progression in prostate cancer patients.